Development of human induced pluripotent stem cells (iPSCs) in patients with neurodegeneration with brain iron accumulation (NBIA) (360G-Wellcome-099371_Z_12_Z)
A Pathfinder Award to Dr Michael Hutton at Eli Lilly, in partnership with Professor John Hardy at UCL, will provide pilot funding for this Industriy-Academic partnership to work on the rare disorders termed Neurodegeneration with brain iron accumulation (NBIA).This is a group of rare, severe neurological disorders that are characterised by parkinsonism, cognitive decline and dystonia. The Award will fund the development of human induced pluripotent stem cells (iPSCs) cells offers a way to develop in vitro models of these diseases in the laboratory, without exact knowledge of the disease mechanism(s). The cell characteristics will enable these models to be amenable to drug treatment from the array of therapeutic compounds held by Lilly going forward.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded | 99809 |
| Applicant Surname | Hutton |
| Approval Committee | Technology Transfer Challenge Committee |
| Award Date | 2012-09-17T00:00:00+00:00 |
| Financial Year | 2011/12 |
| Grant Programme: Title | Pathfinder Award |
| Internal ID | 099371/Z/12/Z |
| Lead Applicant | Dr Mike Hutton |
| Other Applicant(s) | Dr Mike Hutton |
| Partnership Value | 99809 |
| Planned Dates: End Date | 2014-03-31T00:00:00+00:00 |
| Planned Dates: Start Date | 2012-10-01T00:00:00+00:00 |
| Recipient Org: Country | United States |
| Region | International |